News

Clinical trials today are more commonly assessing quality of life and other PRO measures as part of post-approval studies to present evidence on treatment effectiveness. It is crucial, therefore, that clinical teams have a strong plan for the capture and analysis of PROs data, and the resources required to draw clinically meaningful extrapolations.

Real-world evidence (RWE) research is an increasingly important component of biopharmaceutical product development and commercialization. The growing industry need for broader information on real-world effectiveness and safety-both of which will impact the eventual reimbursement and utilization of new products-is driven by regulators, public and private payers, and prescribers, all of whom seek to better understand the impact of a new product in a real-world setting. The result is that real-world evidence is now included earlier in the research and development phase.

The topic of patient centricity remains very active in the clinical trials industry, as the concept continues to emerge and evolve.  The purpose of this Patient Centered Clinical Trials facilitated by our friends at eyeforpharma virtual roundtable is to (a) better understand the definition of patient centricity, (b) uncover challenges associated with industry wide patient centered technology adoption and (c) how patient centricity/engagement technologies will push the biopharmaceutical industry to c

Patient groups “are uniquely positioned” to understand the impact of disease progression, which is central in determining how big and how long clinical trials should be.

Mobile strategies bring near-endless possibilities to engage with patients in clinical trials.

TransCelerate's Quality Management System (QMS) Initiative delineates specific mechanics that will be used to build a QMS Conceptual Framework to facilitate and encourage proactive approaches towards executing Good Clinical Practices, and proper change management expected to support a culture of quality.

The companies believe the CluePoints' Central Statistical Monitoring (CSM) solution that uses statistical methodology to identify unusual patterns in clinical trial databases, will help detect potential data quality problems in CNS trials.

A snapshot of one novel approach in RBM implementation and the data and site performance lessons learned.

.

Democratic candidate Hillary Clinton is introducing her Prescription Drug Plan which is meant to benefit patients, however, will Hillary’s plan be good for advancing novel therapies, and will it benefit R&D organizations?

Addressing the challenges unique to purely industry-sponsored trials is explored.

The successful implementation of centralized monitoring requires effective planning, process restructuring, cross-functional expertise alignment, and the right technology in place.

Rasi was forced to step down in November 2014 by the EU Civil Service Tribunal after a panel of experts found the European Commission (EC) had used improper procedures when it had selected him back in 2011.

Aligning patient-centric approaches with personalized medicine and biomarker use is transforming the design of Alzheimer's trials.

A review of public data indicates a small increase in Phase III inclusion/exclusion criteria per trial over a five-year period.

This experimental technique is being studied to see whether it could treat certain health problems.